Hemab Therapeutics Holdings, Inc. (COAG) Revenue, Earnings & Financial Statements
$39.06NASDAQ: COAGMarket Cap $1.83B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Hemab Therapeutics Holdings, Inc. most recently reported annual revenue of $0, a net loss of $64.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$70.0M
Operating Profit
−$70.0M
Other Income
$6.0M
Interest
$0
Depreciation
$0
Profit Before Tax
−$64.0M
Tax rate (%)
0.3%
Net Profit
−$64.0M
EPS
−$2.33
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
Operating Expenses
$20.0M
$24.0M
$26.0M
$30.0M
Operating Profit
−$20.0M
−$24.0M
−$26.0M
−$30.0M
Interest
$0
$0
$0
$0
Profit Before Tax
−$19.0M
−$23.0M
−$24.0M
−$27.0M
Tax rate (%)
0.7%
-0.1%
-0.4%
-2.6%
Net Profit
−$19.0M
−$23.0M
−$24.0M
−$27.0M
EPS
$0.00
−$0.51
−$0.80
−$0.58
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$195.0M
Current Assets
$193.0M
Cash
$88.0M
Inventory
$0
Receivables
$3.0M
Fixed Assets
$2.0M
Capital Work in Progress
$0
Investments
$98.0M
Other Assets
$0
Total Liabilities
$371.0M
Current Liabilities
$11.0M
Borrowings
$1.0M
Other Liabilities
$370.0M
Equity
$0
Reserves
−$177.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$61.0M
Investing Cash Flow
−$81.0M
Financing Cash Flow
$0
Net Cash Flow
$14.0M
Free Cash Flow
−$61.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.16
EV / EBITDA
-16.46
FCF Yield
-4.89%
Quick Ratio
33.86
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
Hemab Therapeutics Holdings, Inc. (COAG) financials — frequently asked questions
What is Hemab Therapeutics Holdings, Inc.'s annual revenue?
Hemab Therapeutics Holdings, Inc. (COAG) reported annual revenue of $0 in its most recent fiscal year.
What is Hemab Therapeutics Holdings, Inc.'s net profit?
Hemab Therapeutics Holdings, Inc. (COAG) reported a net loss of $64.0M in its most recent fiscal year.
What is COAG EV/EBITDA?
Hemab Therapeutics Holdings, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -16.46. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks